Dietary polyphenols as topoisomerase II poisons: B ring and C ring substituents determine the mechanism of enzyme-mediated DNA cleavage enhancement

Chemical Research in Toxicology

Volumn 21, Issue 6, 2008, Pages 1253-1260

  Bandele, Omari J ^a   Clawson, Sara J ^a   Osheroff, Neil ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IIALPHA; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; FLAVONOL; KAEMPFEROL; MYRICETIN; POLYPHENOL; QUERCETIN;

ARTICLE; CHEMICAL STRUCTURE; DNA CLEAVAGE; ENZYME BINDING; OXIDATION REDUCTION REACTION;

CATECHIN; COLOR; DIET; DNA CLEAVAGE; DNA TOPOISOMERASES, TYPE II; FLAVONOIDS; HUMANS; PHENOLS; TEA;

EID: 47049094564     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx8000785     Document Type: Article

References (100)

1. Kurzer, M. S., and Xu, X. (1997) Dietary phytoestrogens. Annu. Rev. Nutr. 17, 353-381.
2. Scalbert, A., and Williamson, G. (2000) Dietary intake and bioavailability of polyphenols. J. Nutr. 130, 2073S-2085S.
3. Galati, G., and O'Brien, P. J. (2004) Potential toxicity of flavonoids and other dietary phenolics: Significance for their chemopreventive and anticancer properties. Free Radical Biol. Med. 37, 287-303.
4. Yao, L. H., Jiang, Y. M., Shi, J., Tomas-Barberan, F. A., Datta, N., Singanusong, R., and Chen, S. S. (2004) Flavonoids in food and their health benefits. Plant Foods Hum. Nutr. 59, 113-122.
5. Kanadaswami, C., Lee, L. T., Lee, P. P., Hwang, J. J., Ke, F. C., Huang, Y. T., and Lee, M. T. (2005) The antitumor activities of flavonoids. In Vivo 19, 895-909.
6. Siddiqui, I. A., Adhami, V. M., Saleem, M., and Mukhtar, H. (2006) Beneficial effects of tea and its polyphenols against prostate cancer. Mol. Nutr. Food Res. 50, 130-143.
7. Adlercreutz, H., Markkanen, H., and Watanabe, S. (1993) Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 342, 1209-1210.
8. Lamartiniere, C. A. (2000) Protection against breast cancer with genistein: A component of soy. Am. J. Clin. Nutr. 71, 1705S-1709S.
9. Sarkar, F. H., Adsule, S., Padhye, S., Kulkarni, S., and Li, Y. (2006) The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Rev. Med. Chem. 6, 401-407.
10. Usui, T. (2006) Pharmaceutical prospects of phytoestrogens. Endocr. J. 53, 7-20.
11. Ross, J. A., Potter, J. D., and Robison, L. L. (1994) Infant leukemia, topoisomerase II inhibitors, and the MLL gene. J. Natl. Cancer Inst. 86, 1678-1680.
12. Ross, J. A., Potter, J. D., Reaman, G. H., Pendergrass, T. W., and Robison, L. L. (1996) Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): A report from the Children's Cancer Group. Cancer Causes Control 7, 581-590.
13. Ross, J. A. (1998) Maternal diet and infant leukemia: A role for DNA topoisomerase II inhibitors? Int. J. Cancer Suppl. 11, 26-28.
14. Strick, R., Strissel, P. L., Borgers, S., Smith, S. L., and Rowley, J. D. (2000) Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc. Natl. Acad. Sci. 97, 4790-4795.
15. Spector, L. G., Xie, Y., Robison, L. L., Heerema, N. A., Hilden, J. M., Lange, B., Felix, C. A., Davies, S. M., Slavin, J., Potter, J. D., Blair, C. K., Reaman, G. H., and Ross, J. A. (2005) Maternal diet and infant leukemia: The DNA topoisomerase II inhibitor hypothesis: A report from the children's oncology group. Cancer Epidemiol. Biomarkers Prev. 14, 651-655.
16. Sang, S., Hou, Z., Lambert, J. D., and Yang, C. S. (2005) Redox properties of tea polyphenols and related biological activities. Antioxid. Redox Signaling 7, 1704-1714.
17. Isbrucker, R. A., Bausch, J., Edwards, J. A., and Wolz, E. (2006) Safety studies on epigallocatechin gallate (EGCG) preparations. Part 1: Genotoxicity. Food Chem. Toxicol. 44, 626-635.
18. Isbrucker, R. A., Edwards, J. A., Wolz, E., Davidovich, A., and Bausch, J. (2006) Safety studies on epigallocatechin gallate (EGCG) preparations. Part 2: Dermal, acute and short-term toxicity studies. Food Chem. Toxicol. 44, 636-650.
19. Yang, C. S., Lambert, J. D., Ju, J., Lu, G., and Sang, S. (2007) Tea and cancer prevention: Molecular mechanisms and human relevance. Toxicol. Appl. Pharmacol. 224, 265-273.
20. Huafu, W., and Helliwell, K. (2001) Determination of flavonols in green and black tea leaves and green tea infusions by high-performance liquid chromatography. Food Res. Int. 2-3.
21. Hong, J., Lu, H., Meng, X., Ryu, J. H., Hara, Y., and Yang, C. S. (2002) Stability, cellular uptake, biotransformation, and efflux of tea polyphenol (-)-epigallocatechin-3-gallate in HT-29 human colon adenocarcinoma cells. Cancer Res. 62, 7241-7246.
22. Bertram, B., Bollow, U., Rajaee-Behbahani, N., Burkle, A., and Schmezer, P. (2003) Induction of poly(ADP-ribosyl)ation and DNA damage in human peripheral lymphocytes after treatment with (-)-epigallocatechin-gallate. Mutat. Res. 534, 77-84.
23. Weisburg, J. H., Weissman, D. B., Sedaghat, T., and Babich, H. (2004) In vitro cytotoxicity of epigallocatechin gallate and tea extracts to cancerous and normal cells from the human oral cavity. Basic Clin. Pharmacol. Toxicol. 95, 191-200.
24. Kanadzu, M., Lu, Y., and Morimoto, K. (2006) Dual function of (-)-epigallocatechin gallate (EGCG) in healthy human lymphocytes. Cancer Lett. 241, 250-255.
25. Lambert, J. D., Sang, S., and Yang, C. S. (2007) Possible controversy over dietary polyphenols: Benefits vs risks. Chem. Res. Toxicol. 20, 583-585.
26. Noda, C., He, J., Takano, T., Tanaka, C., Kondo, T., Tohyama, K., Yamamura, H., and Tohyama, Y. (2007) Induction of apoptosis by epigallocatechin-3-gallate in human lymphoblastoid B cells. Biochem. Biophys. Res. Commun. 362, 951-957.
27. Markovits, J., Linassier, C., Fosse, P., Couprie, J., Pierre, J., Jacquemin-Sablon, A., Saucier, J. M., Le Pecq, J. B., and Larsen, A. K. (1989) Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res. 49, 5111-5117.
28. Austin, C. A., Patel, S., Ono, K., Nakane, H., and Fisher, L. M. (1992) Site-specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives. Biochem. J. 282, 883-889.
29. Constantinou, A., Mehta, R., Runyan, C., Rao, K., Vaughan, A., and Moon, R. (1995) Flavonoids as DNA topoisomerase antagonists and poisons: Structure-activity relationships. J. Nat. Prod. 58, 217-225.
30. Bandele, O. J., and Osheroff, N. (2007) Bioflavonoids as poisons of human topoisomerase IÍ and IIβ. Biochemistry 46, 6097-6108.
31. Bandele, O. J., and Osheroff, N. (2008) (-)-Epigallocatechin gallate, a major constituent of green tea, poisons human type II topoisomerases. Chem. Res. Toxicol. 21, 936-943.
32. Snyder, R. D., and Gillies, P. J. (2002) Evaluation of the clastogenic, DNA intercalative, and topoisomerase II-interactive properties of bioflavonoids in Chinese hamster V79 cells. Environ. Mol. Mutagen. 40, 266-276.
33. Lynch, A., Harvey, J., Aylott, M., Nicholas, E., Burman, M., Siddiqui, A., Walker, S., and Rees, R. (2003) Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity. Mutagenesis 18, 345-353.
34. van Waalwijk van Doorn-Khosrovani, S. B., Janssen, J., Maas, L. M., Godschalk, R. W., Nijhuis, J. G., and van Schooten, F. J. (2007) Dietary flavonoids induce MLL translocations in primary human CD34+ cells. Carcinogenesis 28, 1703-1709.
35. Berger, J. M. (1998) Type II topoisomerases. Curr.Opin. Struct. Biol. 8, 26-32.
36. Wang, J. C. (1998) Moving one DNA double helix through another by a type II DNA topoismerase: The story of a simple molecular machine. Q. Rev. Biophys. 31, 107-144.
37. Champoux, J. J. (2001) DNA topisomerases: Structure, function, and mechanism. Annu. Rev. Biochem. 70, 369-413.
38. Wilstermann, A. M., and Osheroff, N. (2003) Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr. Top. Med. Chem. 3, 321-338.
39. Corbett, K. D., and Berger, J. M. (2004) Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu. Rev. Biophys. Biomol. Struct. 33, 95-118.
40. McClendon, A. K., and Osheroff, N. (2007) DNA topoisomerase II, genotoxicity, and cancer. Mutat. Res. 623, 83-97.
41. Drake, F. H., Zimmerman, J. P., McCabe, F. L., Bartus, H. F., Per, S. R., Sullivan, D. M., Ross, W. E., Mattern, M. R., Johnson, R. K., and Crooke, S. T. (1987) Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J. Biol. Chem. 262, 16739-16747.
42. Drake, F. H., Hofmann, G. A., Bartus, H. F., Mattern, M. R., Crooke, S. T., and Mirabelli, C. K. (1989) Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28, 8154-8160.
43. Nitiss, J. L. (1998) Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim. Biophys. Acta 1400, 63-81.
44. Austin, C. A., and Marsh, K. L. (1998) Eukaryotic DNA topoisomerase IIβ. BioEssays 20, 215-226.
45. Wang, J. C. (2002) Cellular roles of DNA topoisomerases: A molecular perspective. Nat. Rev. Mol. Cell. Biol. 3, 430-440.
46. Heck, M. M., and Earnshaw, W. C. (1986) Topoisomerase II: A specific marker for cell proliferation. J. Cell Biol. 103, 2569-2581.
47. Hsiang, Y. H., Wu, H. Y., and Liu, L. F. (1988) Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res. 48, 3230-3235.
48. Woessner, R. D., Mattern, M. R., Mirabelli, C. K., Johnson, R. K., and Drake, F. H. (1991) Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 2, 209-214.
49. Chen, M., and Beck, W. T. (1995) DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines. Oncol. Res. 7, 103-111.
50. Yang, X., Li, W., Prescott, E. D., Burden, S. J., and Wang, J. C. (2000) DNA topoisomerase IIβ and neural development. Science 287, 131-134.
51. Dereuddre, S., Delaporte, C., and Jacquemin-Sablon, A. (1997) Role of topoisomerase IIβ in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors. Cancer Res. 57, 4301-4308.
52. Grue, P., Grasser, A., Sehested, M., Jensen, P. B., Uhse, A., Straub, T., Ness, W., and Boege, F. (1998) Essential mitotic functions of DNA topoisomerase IIα are not adopted by topoisomerase IIβ in human H69 cells. J. Biol. Chem. 273, 33660-33666.
53. Sander, M., and Hsieh, T. (1983) Double strand DNA cleavage by type II DNA topoisomerase from Drosophila melanogaster. J. Biol. Chem. 258, 8421-8428.
54. Liu, L. F., Rowe, T. C., Yang, L., Tewey, K. M., and Chen, G. L. (1983) Cleavage of DNA by mammalian DNA topoisomerase II. J. Biol. Chem. 258, 15365-15370.
55. Zechiedrich, E. L., Christiansen, K., Andersen, A. H., Westergaard, O., and Osheroff, N. (1989) Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: Evidence for a nicked DNA intermediate. Biochemistry 28, 6229-6236.
56. Baguley, B. C., and Ferguson, L. R. (1998) Mutagenic properties of topoisomerase-targeted drugs. Biochim. Biophys. Acta 1400, 213-222.
57. Kaufmann, S. H. (1998) Cell death induced by topoisomerase-targeted drugs: More questions than answers. Biochim. Biophys. Acta 1400, 195-211.
58. Felix, C. A. (1998) Secondary leukemias induced by topoisomerase-targeted drugs. Biochim. Biophys. Acta 1400, 233-255.
59. Kreuzer, K. N., and Cozzarelli, N. R. (1979) Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: Effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth. J. Bacteriol. 140, 424-435.
60. Li, T. K., and Liu, L. F. (2001) Tumor cell death induced by topoisomerase-targeting drugs. Annu. Rev. Pharmacol. Toxicol. 41, 53-77.
61. Walker, J. V., and Nitiss, J. L. (2002) DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest. 20, 570-589.
62. Pommier, Y., and Marchand, C. (2005) Interfacial inhibitors of protein-nucleic acid interactions. Curr. Med. Chem. Anti-Cancer Agents 5, 421-429.
63. Hande, K. R. (1998) Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim. Biophys. Acta 1400, 173-184.
64. Hande, K. R. (1998) Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer 34, 1514-1521.
65. Baldwin, E. L., and Osheroff, N. (2005) Etoposide, topoisomerase II and cancer. Curr. Med. Chem. Anticancer Agents 5, 363-372.
66. Felix, C. A., Kolaris, C. P., and Osheroff, N. (2006) Topoisomerase II and the etiology of chromosomal translocations. DNA Repair (Amsterdam) 5, 1093-1108.
67. Rowley, J. D. (1994) 1993 Robert R. de Villiers Lecture. Chromosome translocations: Dangerous liaisons. Leukemia 8, S1-S6.
68. Smith, M. A., Rubinstein, L., Anderson, J. R., Arthur, D., Catalano, P. J., Freidlin, B., Heyn, R., Khayat, A., Krailo, M., Land, V. J., Miser, J., Shuster, J., and Vena, D. (1999) Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J. Clin. Oncol. 17, 569-577.
69. Felix, C. A. (2001) Leukemias related to treatment with DNA topoisomerase II inhibitors. Med. Pediatr. Oncol. 36, 525-535.
70. Andersen, M. K., Christiansen, D. H., Jensen, B. A., Ernst, P., Hauge, G., and Pedersen-Bjergaard, J. (2001) Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: Report on two new cases and review of the literature since 1992. Br. J. Hamaetol. 114, 539-543.
71. Kingma, P. S., Corbett, A. H., Burcham, P. C., Marnett, L. J., and Osheroff, N. (1995) Abasic sites stimulate double-stranded DNA cleavage mediated by topoisomerase II: Anticancer drugs mimic endogenous DNA lesions. J. Biol. Chem. 270, 21441-21444.
72. Kingma, P. S., and Osheroff, N. (1997) Spontaneous DNA damage stimulates topoisomerase II-mediated DNA cleavage. J. Biol. Chem. 272, 7488-7493.
73. Cline, S. D., Jones, W. R., Stone, M. P., and Osheroff, N. (1999) DNA abasic lesions in a different light: Solution structure of an endogenous topoisomerase II poison. Biochemistry 38, 15500-15507.
74. Sabourin, M., and Osheroff, N. (2000) Sensitivity of human type II topoisomerases to DNA damage: Stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions. Nucleic Acids Res. 28, 1947-1954.
75. Velez-Cruz, R., Riggins, J. N., Daniels, J. S., Cai, H., Guengerich, F. P., Marnett, L. J., and Osheroff, N. (2005) Exocyclic DNA lesions stimulate DNA cleavage mediated by human topoisomerase IIα in vitro and in cultured cells. Biochemistry 44, 3972-3981.
76. Lindsey, R. H., Jr., Bromberg, K. D., Felix, C. A., and Osheroff, N. (2004) 1,4-Benzoquinone is a topoisomerase II poison. Biochemistry 43, 7563-7574.
77. Wang, H., Mao, Y., Chen, A. Y., Zhou, N., LaVoie, E. J., and Liu, L. F. (2001) Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation. Biochemistry 40, 3316-3323.
78. Bender, R. P., Lindsey, R. H., Jr., Burden, D. A., and Osheroff, N. (2004) N-acetyl-p-benzoquinone imine, the toxic metabolite of acetaminophen, is a topoisomerase II poison. Biochemistry 43, 3731-3739.
79. Bender, R. P., Lehmler, H. J., Robertson, L. W., Ludewig, G., and Osheroff, N. (2006) Polychlorinated biphenyl quinone metabolites poison human topoisomerase IIα: Altering enzyme function by blocking the N-terminal protein gate. Biochemistry 45, 10140-10152.
80. Bender, R. P., and Osheroff, N. (2007) Mutation of cysteine residue 455 to alanine in human topoisomerase IIα confers hypersensitivity to quinones: Enhancing DNA scission by closing the N-terminal protein gate. Chem. Res. Toxicol. 20, 975-981.
81. Bender, R. P., Ham, A. J., and Osheroff, N. (2007) Quinone-induced enhancement of DNA cleavage by human topoisomerase IIα: Adduction of cysteine residues 392 and 405. Biochemistry 46, 2856-2864.
82. Bender, R. P., and Osheroff, N. (2007) DNA topoisomerases as targets for the chemotherapeutic treatment of cancer. In Cancer Drug Discovery and Development Checkpoint Responses in Cancer Therapy (Dai, W., Ed.) pp 59-92, Humana Press, Totowa, NJ.
83. Frantz, C. E., Chen, H., and Eastmond, D. A. (1996) Inhibition of human topoisomerase II in vitro by bioactive benzene metabolites. Environ. Health Perspect. 104 (Suppl. 6), 1319-1323.
84. Baker, R. K., Kurz, E. U., Pyatt, D. W., Irons, R. D., and Kroll, D. J. (2001) Benzene metabolites antagonize etoposide-stabilized cleavable complexes of DNA topoisomerase IIα. Blood 98, 830-833.
85. Langley-Evans, S. C. (2000) Antioxidant potential of green and black tea determined using the ferric reducing power (FRAP) assay. Int. J. Food Sci. Nutr. 51, 181-188.
86. Valcic, S., Muders, A., Jacobsen, N. E., Liebler, D. C., and Timmermann, B. N. (1999) Antioxidant chemistry of green tea catechins. Identification of products of the reaction of (-)-epigallocatechin gallate with peroxyl radicals. Chem. Res. Toxicol. 12, 382-386.
87. Valcic, S., Burr, J. A., Timmermann, B. N., and Liebler, D. C. (2000) Antioxidant chemistry of green tea catechins. New oxidation products of (-)-epigallocatechin gallate and (-)-epigallocatechin from their reactions with peroxyl radicals. Chem. Res. Toxicol. 13, 801-810.
88. Lambert, J. D., and Yang, C. S. (2003) Mechanisms of cancer prevention by tea constituents. J. Nutr. 133, 3262S-3267S.
89. Sang, S., Lambert, J. D., Hong, J., Tian, S., Lee, M. J., Stark, R. E., Ho, C. T., and Yang, C. S. (2005) Synthesis and structure identification of thiol conjugates of (-)-epigallocatechin gallate and their urinary levels in mice. Chem. Res. Toxicol. 18, 1762-1769.
90. Worland, S. T., and Wang, J. C. (1989) Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae. J. Biol. Chem. 264, 4412-4416.
91. Elsea, S. H., Hsiung, Y., Nitiss, J. L., and Osheroff, N. (1995) A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine. J. Biol. Chem. 270, 1913-1920.
92. Kingma, P. S., Greider, C. A., and Osheroff, N. (1997) Spontaneous DNA lesions poison human topoisomerase IIα and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints. Biochemistry 36, 5934-5939.
93. Fortune, J. M., and Osheroff, N. (1998) Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage. J. Biol. Chem. 273, 17643-17650.
94. Gradisar, H., Pristovsek, P., Plaper, A., and Jerala, R. (2007) Green tea catechins inhibit bacterial DNA gyrase by interaction with its ATP binding site. J. Med. Chem. 50, 264-271.
95. Salah, N., Miller, N. J., Paganga, G., Tijburg, L., Bolwell, G. P., and Rice-Evans, C. (1995) Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Arch. Biochem. Biophys. 322, 339-346.
96. Rice-Evans, C. A., Miller, N. J., and Paganga, G. (1996) Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radical Biol. Med. 20, 933-956.
97. Guo, Q., Zhao, B., Shen, S., Hou, J., Hu, J., and Xin, W. (1999) ESR study on the structure-antioxidant activity relationship of tea catechins and their epimers. Biochim. Biophys. Acta 1427, 13-23.
98. Yang, C. S., Chung, J. Y., Yang, G., Chhabra, S. K., and Lee, M. J. (2000) Tea and tea polyphenols in cancer prevention. J. Nutr. 130, 472S-478S.
99. Chen, H., and Eastmond, D. A. (1995) Topoisomerase inhibition by phenolic metabolites: A potential mechanism for benzene's clastogenic effects. Carcinogenesis 16, 2301-2307.
100. Kozerski, L., Kamienski, B., Kawecki, R., Urbanczyk-Lipkowska, Z., Bocian, W., Bednarek, E., Sitkowski, J., Zakrzewska, K., Nielsen, K. T., and Hansen, P. E. (2003) Solution and solid state 13C NMR and X-ray studies of genistein complexes with amines. Potential biological function of the C-7, C-5, and C4′-OH groups. Org. Biomol. Chem. 1, 3578-3585.